Mesenchymal Stem Cells (MSC), also termed Mesenchymal Stromal Cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal. MSC have been shown to differentiate in vitro or in vivo into adipocytes, chondrocytes, osteoblasts, myocytes, neurons, hepatocytes, and pancreatic islet cells. Optimized PromoCell media are available to support both the growth of MSC and their differentiation into several different lineages. Recent experiments suggest that differentiation capabilities into diverse cell types vary between MSC of different origin. LPI (LP Information)' newest research report, the “Mesenchymal Stem Cells Industry Forecast” looks at past sales and reviews total world Mesenchymal Stem Cells sales in 2022, providing a comprehensive analysis by region and market sector of projected Mesenchymal Stem Cells sales for 2023 through 2029. With Mesenchymal Stem Cells sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mesenchymal Stem Cells industry. This Insight Report provides a comprehensive analysis of the global Mesenchymal Stem Cells landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Mesenchymal Stem Cells portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mesenchymal Stem Cells market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mesenchymal Stem Cells and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mesenchymal Stem Cells. The global Mesenchymal Stem Cells market size is projected to grow from US$ 202.6 million in 2022 to US$ 278.8 million in 2029; it is expected to grow at a CAGR of 4.7% from 2023 to 2029. The top 3 manufacturters of Mesenchymal Stem Cells include Lonza, Thermo Fisher and Bio-Techne, with about 56% market shares. North America region is the largest consumption of Mesenchymal Stem Cells, with a sales revenue market share nearly 41%. Europe is the second largest consumer of Mesenchymal Stem Cells, enjoying sales revenue market share about 31%. This report presents a comprehensive overview, market shares, and growth opportunities of Mesenchymal Stem Cells market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Human MSC Mouse MSC Rat MSC Others Segmentation by application Research Institute Hospital Others This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Lonza Thermo Fisher Bio-Techne ATCC MilliporeSigma PromoCell GmbH Genlantis Celprogen Cell Applications Cyagen Biosciences Axol Bioscience
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Mesenchymal Stem Cells Market Size 2018-2029 2.1.2
